PharmaSUG China 2025 - Paper DS-122

From Statistical Programmer's Desk: Conquering FDA Inspections with Effective Quality Control Measures

Hao Dong, Dizal Pharma

ABSTRACT

Inspections are a critical component of the regulatory submission process, serving as a gateway to ensure the safety, efficacy, and compliance of pharmaceutical products. This paper highlights the importance of ensuring compliance and quality in these inspections, with a focus on the role of statistical programmers as a crucial yet often underrepresented component. We explore effective quality control measures for preparing for and successfully navigating these rigorous evaluations. The preparation phase involves comprehensive scopes, adherence to SOPs and WIs, meticulous documentation, and mock inspections to ensure readiness.

Drawing from Dizal's real-life inspection experiences, the paper provides insights into the practical aspects and challenges faced by statistical programmers within the broader inspection team. By understanding their role within the inspection process, preparing thoroughly, and adhering to best practices, statistical programmers can contribute meaningfully to the overall quality and compliance of pharmaceutical projects, ultimately supporting the success of FDA inspections and the trustworthiness of medical products.

INTRODUCTION

The pharmaceutical industry operates under stringent regulatory oversight to ensure the safety and efficacy of medical products. Among the key regulatory bodies is the Food and Drug Administration (FDA), which conducts rigorous inspections as part of the submission and approval process. These inspections are essential for verifying that manufacturing facilities, clinical studies, and other aspects of drug development comply with established laws and regulations.

Within the intricate web of compliance and quality assurance, statistical programmers play an indispensable role, albeit often overlooked. They are responsible for creating, reviewing, and validating statistical programming outputs that are crucial for demonstrating the safety and effectiveness of drugs. However, the unique challenges faced by statistical programmers during FDA inspections are not widely discussed.

This paper seeks to provide insights into the preparation, role, and challenges of statistical programmers during FDA inspections. By drawing upon real-world inspection scenarios and offering actionable advice, we aim to enhance the understanding and capabilities of statistical programmers. This, in turn, will contribute to the successful execution of their responsibilities within pharmaceutical projects.

A COMPREHENSIVE LOOK AT THE FDA INSPECTION PROCESS

UNDERSTANDING FDA INSPECTIONS AND TYPES

An FDA inspection is a mandatory process conducted by the Food and Drug Administration (FDA) to ensure compliance with regulations across various industries, including food, drug, medical device, cosmetic, and tobacco industries. These inspections are legally binding and can lead to regulatory actions if non-compliance is found. Unlike audits, which are typically non-binding assessments of trial conduct and documentation, FDA inspections are enforced by government officials and may result in formal actions to address compliance issues.

FDA inspections are categorized into several types, each tailored to specific regulatory needs:

1. Routine Inspections: These are scheduled periodic checks designed to monitor ongoing compliance with FDA regulations. They cover a broad range of operations, ensuring that facilities consistently meet regulatory standards.
2. For-Cause Inspections: Also known as unannounced or surprise inspections, these are initiated in response to specific concerns, such as consumer complaints, adverse event reports, or previous inspection findings indicating potential non-compliance. They aim to address immediate issues and ensure corrective actions are taken promptly.
3. Pre-Approval Inspections: Conducted prior to the approval of new products or facilities, these inspections verify that manufacturing facilities meet necessary quality and safety standards. They are critical for ensuring that new products entering the market are produced under compliant conditions.
4. Follow-Up Inspections: Scheduled to verify that corrective actions taken in response to previous inspection findings have been effectively implemented. These inspections ensure that non-compliance issues have been adequately addressed.

Understanding the different types of FDA inspections is essential for organizations to prepare effectively and maintain compliance with regulatory requirements. By addressing specific risks and ensuring ongoing adherence to standards, businesses can demonstrate their commitment to public health and the safety of FDA-regulated products.

OUTPUT OF THE FDA INSPECTION

During an inspection, investigators may identify objectionable conditions, which are documented on Form FDA 483. This form alerts the company's management to the observed issues and is presented to and discussed with company management at the end of the inspection. From FY2020 to FY2024, the number of 483s issued annually in drug inspections were 349, 215, 466, 510, and 561, respectively. These figures indicate a gradual recovery following the COVID-19 pandemic; however, the numbers remain below pre-pandemic levels.

Table 1 illustrates the 10 most frequently cited inspection observations between FY2020 and FY2024, whereas the FDA website provides a comprehensive tabulation of all citations issued during each fiscal year. This article presents the most recent data on drug inspections conducted in FY2024, analyzing trends in FDA enforcement over the past five years. The FDA defines "frequency" as the number of times a specific citation was identified in its tabulation. Table 1 ranks these observations from highest to lowest frequency for FY2024, revealing a consistent pattern in the most frequently cited regulations over the years. The four most frequently cited regulations in FY2024 were: 21 CFR 211.22(d) (Procedures not in writing, fully followed), 21 CFR 211.192 (Investigations of discrepancies, failures), 21 CFR 211.100(a) (Absence of Written Procedures), and 21 CFR 211.160(b) (Scientifically sound laboratory controls). These findings highlight the FDA's ongoing emphasis on standardized processes in ensuring quality control.

REFERENCE NUMBER	SHORT DESCRIPTION	2020	2021	2022	2023	2024
Total Form 483s issued using the FDA tool for Drug Inspections		349	215	466	510	561
21 CFR 211.22(d)	Procedures not in writing, fully followed	111	80	161	152	201
21 CFR 211.192	Investigations of discrepancies, failures	79	49	104	114	134
21 CFR 211.100(a)	Absence of Written Procedures	46	44	81	86	126
21 CFR 211.160(b)	Scientifically sound laboratory controls	58	40	78	84	119
21 CFR 211.63	Equipment Design, Size and Location	44	25	60	74	85

21 CFR 211.67(a)	Cleaning / Sanitizing / Maintenance	42	33	50	68	76
21 CFR 211.113(b)	Procedures for sterile drug products	31	22	39	62	69
21 CFR 211.67(b)	Written procedures not established/followed	26	15	35	35	60
21 CFR 211.68(b)	Computer control of master formula records	38	30	56	61	60
21 CFR 211.166(a)	Lack of written stability program	18	15	30	18	47

Table 1 Drug Inspections, 21 CFR 211 Citation Frequency by Fiscal Year

Form 483 does not serve as a final determination of regulatory violations. It is considered alongside the Establishment Inspection Report, on-site evidence, and company responses to inform FDA's decision-making. FDA inspection outcomes significantly influence a pharmaceutical company's operational and strategic direction.

The FDA categorizes inspection outcomes into three main classifications: No Action Indicated (NAI), Voluntary Actions Indicated (VAI), and Official Action Indicated (OAI). An NAI outcome signifies full compliance with regulatory requirements, reinforcing the company's credibility and stakeholder confidence. Conversely, a VAI outcome indicates minor deviations requiring corrective actions, prompting companies to address these issues proactively. The most severe outcome, OAI, signals significant violations necessitating enforcement actions, which can lead to reputational damage and financial losses.

To mitigate the risk of adverse outcomes, companies must prioritize robust quality control measures, employee training on regulatory standards, and comprehensive compliance programs. These efforts not only safeguard operational integrity but also facilitate future collaborations and strengthen market positioning.

FDA inspection outcomes play a pivotal role in shaping the operational landscape of pharmaceutical companies. By understanding and addressing the implications of each outcome classification, companies can enhance their quality systems and compliance strategies, ultimately ensuring successful and sustainable operations.

PREPARATION FOR FDA INSPECTION: BUILDING A ROBUST FOUNDATION

INSPECTION READINESS

The inspection readiness process is a critical component of ensuring compliance with regulatory requirements and fostering a culture of quality within an organization. For companies or employees undergoing their first FDA inspection, comprehensive training is essential. Conducting an inspection without proper preparation can lead to significant challenges, including potential non-compliance issues. The primary objective of inspection training is to ensure that all necessary processes, personnel, documentation, and electronic systems are in place to meet the standards set by sponsors, contract research organizations (CROs), or other vendors. This includes adherence to standard operating procedures (SOPs), protocols, and applicable regulatory requirements at all times.

Behavioral training is a key aspect of inspection readiness. Employees should be instructed on appropriate conduct during inspections, including the avoidance of certain phrases during interviews, professional attire, and the preparation of materials for review. Additionally, training should emphasize the importance of maintaining a cooperative and transparent relationship with inspectors throughout the process.

The foundation of quality control measures lies in the development and implementation of SOPs and work instructions (WIs). These documents must be up-to-date, reflecting the latest regulatory requirements and internal best practices. They should also be clear and concise to avoid ambiguity, ensuring consistent

interpretation and execution across all team members. Equally important is the thorough training of all staff on relevant SOPs and WIs, as this ensures that everyone is aligned with the organization's quality objectives and regulatory obligations.

Documentation is a cornerstone of demonstrating compliance and the effectiveness of quality control measures. The trial master file (TMF) is particularly critical, as it contains essential records and information related to a clinical trial. Ensuring that the TMF is well-managed and free of missing or incomplete files is vital. Key aspects of documentation include maintaining detailed verification records, ensuring the accuracy of file timestamps, and organizing training records for easy access during inspections. Version control is another critical consideration, as it helps prevent confusion and ensures that the most current versions of all documents are used consistently.

To facilitate effective communication during inspections, the preparation of a storyboard is highly recommended. This visual aid should provide a comprehensive overview of the organization's structure, functional roles and responsibilities, workflow, and data flow. It should also address any other issue that may require clarification for inspectors. Importantly, the storyboard should adhere to the company's internal template and reflect alignment across all relevant functions. For example, in the case of PK data flow, the workflow may involve collaboration between clinical pharmacology, data management, and statistical programming. Ensuring that all functions have had the opportunity to review and discuss the flow in advance helps prevent discrepancies and ensures consistency in responses.

To enhance readiness for FDA inspections, it is highly recommended to develop a question pool in advance. Each functional team should brainstorm potential questions an inspector might ask and compile them with corresponding answers. This exercise fosters thorough understanding and ensures all team members are well-prepared. Familiarizing everyone with these scenarios helps build confidence and enables effective responses during the inspection, ultimately contributing to a successful outcome.

In summary, the preparation phase for an FDA inspection is a multifaceted process that requires attention to detail, comprehensive training, and robust documentation practices. By prioritizing these elements, organizations can build a strong foundation for success, ensuring compliance with regulatory requirements and minimizing the risk of adverse outcomes during inspections.

MOCK INSPECTION

A mock inspection is a simulated FDA inspection conducted internally by the organization to prepare for the actual inspection. It involves a team of internal auditors or external consultants who act as FDA inspectors, evaluating the readiness of the organization and its staff. The goal is to identify potential gaps, weaknesses, or areas for improvement before the real inspection.

Dizal's statistical programmers had gained valuable insights from the mock inspection. The mock inspector requested a demonstration of the programming environment, with emphasis placed on the folder structure and access control. A critical consideration was the source data path for development and production mode, with the recommendation that the same path should be maintained across modes to prevent potential inconsistencies. The mock inspector also requested a demonstration of the programming verification process and documentation, with a special focus on file timestamps.

Another key focus of the mock inspector was data transfer and storage process after DM receives the data, which is usually not described in the data flow SOP. It highlights the importance of minimizing risks during data transmission. While cloud storage services like SharePoint and Box are commonly used, they pose significant risks due to the inability to fully ensure protection against unauthorized tampering. Similarly, transmitting data via email attachments introduces risks, as data may be temporarily stored locally before being stored in the programming environment, leaving intermediate steps untraceable. To address these concerns, the consultant recommended implementing alternative secure methods for data transfer and storage to ensure data integrity and security throughout the process.

A data tracing exercise is a critical component of mock inspections, particularly for statistical programmers. It involves tracing data from its source through various stages of processing, cleaning, and analysis to ensure accuracy and integrity. Statistical programmers can prepare your "cheat sheet" containing key information such as imputation rules, complex algorithms, and other critical processes

used in the data handling workflow. It serves as a quick reference guide during the inspection, ensuring that programmers can confidently explain their methods and justify their decisions.

One of the most valuable outcomes of a mock inspection is the identification of issues or areas for improvement. These issues should be documented and addressed through a corrective and preventive action (CAPA) process before the real inspection. The CAPA process involves identifying the root cause of the issue, developing and implementing corrective actions, and establishing preventive measures to avoid recurrence. By documenting and resolving issues during the mock inspection phase, statistical programmers and the broader team can demonstrate a commitment to continuous improvement and ensure that the organization is fully prepared for the real inspection. This proactive approach not only strengthens compliance but also builds confidence among team members.

STATISTICAL PROGRAMMER'S INSPECTION EXPERIENCE

From the perspective of a statistical programmer, this chapter presents insights into FDA inspections based on real-world experiences. Following the submission of a New Drug Application (NDA), the FDA conducted several inspections, including site inspections and vendor inspections (e.g., for pharmacokinetics, companion diagnostics, central imaging, etc.). Since the entire study was fully outsourced, a sponsor inspection was not conducted.

Approximately one month before the scheduled inspection, the agency notified us of the inspection date, allowing adequate time for preparation. For statistical programmers, providing data listings was a critical component of both the preparation phase and the inspection process. Collaboration with the study team was essential to define the scope of the listings, particularly focusing on the sites designated for inspection. This collaborative effort ensured that the listings were comprehensive and aligned with the inspection objectives.

The inspection of a single site typically lasted 3-5 days. Each morning, inspectors provided an agenda outlining the planned activities for the day. It should be noted that inspectors do not always follow the agenda strictly. Inspectors conducted interviews with key personnel and reviewed relevant documents to understand the study setup, workflow, and data management processes. Based on the experience, the initial days of the inspection were primarily focused on gaining an understanding of the study setup, data collection processes, and the workflow within the site.

As the inspection progressed, inspectors began to review the source data in greater detail, comparing it with the submitted Bioresearch Monitoring (BIMO) listings. The submission of high-quality BIMO listings to the FDA is of critical importance. Statistical programmers could anticipate an increase in requests from inspectors in the later days of the inspection. These requests often involved detailed reviews of the data, comparisons between source data and the listings, and explanations of discrepancies or data handling processes. During the inspection, the FDA inspector observed that some AEs with higher CTCAE grades lacked corresponding action taken to study drug recorded in the BIMO listing. The Dizal programmer explained that per the eCRF Completion Guideline (CCG), only the most severe action is recorded for an AE, prioritizing actions in the order of permanent discontinuation, dose reduction, interruption, or no change. Additionally, there is no direct correlation between toxicity grade changes and the actions taken. This explanation was deemed acceptable by the inspector.

When responding to inspector requests, it was important to provide formal and comprehensive answers rather than simple, brief responses. A well-structured and detailed explanation not only demonstrated a clear understanding of the data and processes but also facilitated the inspectors' comprehension of the explanations provided. To prevent issues from escalating, it was essential to address requests promptly and provide responses before the end of the day, as inspectors typically concluded their activities at the end of each day.

In conclusion, the role of a statistical programmer during FDA inspections is multifaceted, requiring meticulous preparation, effective communication, and prompt responsiveness. By adhering to these principles, statistical programmers can ensure the integrity of the data, facilitate a smooth inspection process, and ultimately contribute to the successful evaluation of the pharmaceutical product under review.

DISCUSSION AND CONCLUSION

As can be reflected from historical 483 issues, FDA inspections place a significant emphasis on the TMF, underscoring the critical importance of documentation. This serves as a reminder of the broader responsibilities of statistical programmers beyond their technical expertise in programming. While proficiency in SAS is undeniably essential, it is equally important to recognize that programming skills alone cannot guarantee compliance or success during inspections. The role of statistical programmers extends to ensuring that processes and documentation align with regulatory expectations, particularly in the context of data integrity and quality control.

One key aspect of preparing for FDA inspections is understanding how to properly file and manage quality issues. These measures ensure that any discrepancies or deviations are systematically addressed, documented, and resolved, which is a critical component of demonstrating compliance to inspectors. The FDA emphasizes the importance of corrective and preventive actions (CAPA) to address non-conformities, requiring companies to implement robust systems for identifying root causes, documenting corrective actions, and preventing recurrence. Properly managing quality issues also involves maintaining thorough records of investigations, corrective actions, and follow-up assessments to showcase adherence to regulatory standards. By ensuring transparency, accountability, and continuous improvement, organizations can effectively demonstrate compliance and mitigate risks during inspections.

BIMO listing is usually not the focus of statistical programmers because it does not require derivation and is not within the scope of statistical analysis plan (SAP). However, from Dizal's inspection experience, one of our inspection requests was related to BIMO listing wording (a misleading column header). This highlights the importance of ensuring that BIMO documentation is accurate, complete, and aligned with regulatory standards. Statistical programmers should familiarize themselves with BIMO listings, as inspectors will inevitably scrutinize data within these listings. To effectively respond to inspector's requests, it is crucial to act swiftly and ensure that the responses were well-prepared and thorough. This necessitated advance training for the team, designating a primary responder, and establishing a support system to handle other situations that might arise during the inspection.

Data integrity is a critical component of FDA inspections, particularly for statistical programmers who play a vital role in ensuring the accuracy and reliability of data throughout its lifecycle. Statistical programmers must be prepared to demonstrate that the data they work with is complete, accurate, and reliable, by reviewing audit trails, metadata, and other records that document the data lifecycle. Inspectors often scrutinize how data is collected, stored, processed, and analyzed, as well as how discrepancies or errors are handled.

The success of an inspection hinges on the implementation of robust quality control measures, which are inherently aligned with submission preparation. A comprehensive approach to quality control, integrated throughout the project lifecycle, is essential rather than addressing it only at the final stages. While the establishment of a well-defined SOP is foundational, effective implementation requires additional tools and methodologies. For instance, creating flowcharts to visually represent the project workflow enhances understanding and ensures systematic SOP implementation. Additionally, identifying potential risks, setting system reminders at high-risk and key milestones, helps reduce errors during operations. Incorporating such tools and strategies into workflows streamlines processes, promotes a more organized and transparent approach to quality control, and is essential for statistical programmers to demonstrate compliance and successfully navigate FDA inspections.

REFERENCES

Clark, Donald S. November 18, 2016. "21 CFR Parts 201 and 211." *Federal Register,* Vol. 81, No. 223.

Mekhala Acharya, Kaitlyn Buff, and Norihiko Oharu. 2023. "Submission Survival Guidelines for Statistical Programmers." (2023). *Proceedings of the PharmaSUG 2023*. Available at https://pharmasug.org/proceedings/2023/PO/PharmaSUG-2023-PO-067.pdf.

Natalie Simpson. 2024. "FDA Inspections/Sponsor Audits: Notification Process." *Fred Hutch/University of Washington/Seattle Children's Cancer Consortium.* Available at https://www.cancerconsortium.org/content/dam/consortium/research-support/clinical-research-

support/policies/FDA%20Inspections-Sponsor%20Audits-%20Notification%20Process.pdf.

Unger, Barbara. 2021. "FDA FY2020 Drug Inspection Observations and Trends." *Redica Systems.* Available at https://redica.com/wp-content/uploads/FDA-FY2020-Drug-Inspection-Observations-and-Trends.pdf.

ACKNOWLEDGMENTS

Special thanks are extended to Huadan Li and Jianyong Tong for their insights.

CONTACT INFORMATION

Your comments and questions are valued and encouraged. Contact the author at:

Hao Dong
Dizal Pharma
hao.dong@dizalpharma.com